



## (51) International Patent Classification:

C07D 213/16 (2006.01) C07D 317/06 (2006.01)  
C07D 305/04 (2006.01) C07C 235/54 (2006.01)  
C07D 309/08 (2006.01) A61K 31/085 (2006.01)  
C07D 335/14 (2006.01)

Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US).

## (21) International Application Number:

PCT/US2010/055035

## (22) International Filing Date:

2 November 2010 (02.11.2010)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

09290831.8 2 November 2009 (02.11.2009) EP  
61/319,619 31 March 2010 (31.03.2010) US

(71) Applicant (for all designated States except US):  
**SANOFI-AVENTIS** [FR/FR]; 174 avenue de France,  
F-75013 Paris (FR).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **PERNERSTORFER, Josef** [AT/DE]; c/o Sanofi-aventis Deutschland GMBH, Industriepark Hoechst, Building K801, 65926 Frankfurt am Main (DE). **KLEEMANN, Heinz-Werner** [DE/DE]; c/o Sanofi-aventis Deutschland GMBH, Industriepark Hoechst, Building K801, 65926 Frankfurt am Main (DE). **SCHAEFER, Matthias** [DE/DE]; c/o Sanofi-aventis Deutschland GMBH, Industriepark Hoechst, Building K801, 65926 Frankfurt am Main (DE). **SAFAROVA, Alena** [CZ/US]; c/o SANOFI-AVENTIS U.S., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **PATEK, Marcel** [US/US]; c/o Sanofi-aventis U.S., 1041 Route 202-206,

(74) Agents: **LIN, Jiang** et al.; Sanofi-aventis U.S. Inc., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


## Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

## Published:

- with international search report (Art. 21(3))

(54) Title: ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS



(I)

(57) Abstract: The present invention relates to compounds of the formula (I) wherein A, Y, Z, R<sup>20</sup> to R<sup>22</sup> and R<sup>50</sup> have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA<sub>1</sub> receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.